NOV1601(CHC2014) for Clinical Trials

Phase 1

Waitlist Available

Led By Dong-Wan Kim, MD, PhD

Research Sponsored by National OncoVenture

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up maximum 2 years

Awards & highlights

No Placebo-Only Group

Summary

This study is a first-in-human (FIH) study which is required to understand the PK characteristics, MTD, and safety profile of NOV1601(CHC2014) in subjects with solid organ malignancies.

Eligible Conditions

Clinical Trials
Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ maximum 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~maximum 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and maximum 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

the recommended Phase 2 dose(RP2D) or the maximum tolerated dose(MTD) of NOV1601

Secondary study objectives

Number of participants with treatment-related adverse events(TEAE) and serious adverse events(SAE)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: NOV1601(CHC2014)Experimental Treatment1 Intervention

a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A(TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

NOV1601(CHC2014)

2019

Completed Phase 1

~20

Do I qualify?Apply below to find out